Check Point Software: AI Could Change The Growth Equation

Check Point is assessed as undervalued at $137 per share versus an estimated intrinsic value of $166, implying a 21% margin of safety. The thesis assumes revenue growth accelerates to 10% in Year 1 as the company evolves into an AI-centric cybersecurity platform. Its installed base and asset-light model could support faster revenue and profit growth if fixed costs remain controlled.

Analysis

The core debate is not whether CHKP can add AI features, but whether those features change its net-new billings trajectory versus merely defend a mature firewall estate. CHKP's installed base and high renewal mix create operating leverage if subscription/security-services attach rates rise, but the same installed base can cap upside if customers consolidate toward PANW, CRWD or ZS for endpoint, cloud and SASE. The relevant KPI is therefore RPO/deferred-revenue growth and Quantum/SASE subscription mix—not headline EPS, which can be supported by buybacks even if competitive share erodes.

Near term, the setup is likely asymmetric only if consensus is still modeling low-to-mid-single-digit billings growth while margins remain stable. A 1-3 month rerating catalyst would require evidence that product bookings, especially SASE and cloud security, are growing faster than legacy appliances; absent that, the valuation discount may correctly reflect slower growth and lower platform breadth. Over 6-18 months, fixed-cost discipline could produce disproportionate EPS upside, but aggressive AI-led pricing or elevated channel incentives would falsify the margin case quickly.

Contrarian risk is that “AI cybersecurity” becomes a category-wide valuation label rather than a differentiated revenue driver. PANW has the strongest consolidation narrative, CRWD has the clearest AI-native endpoint data advantage, and FTNT can compete aggressively on appliance economics; CHKP needs measurable conversion of its installed base to recurring subscriptions to avoid remaining a value trap. Treat any valuation target derived from a step-change in growth as scenario-dependent until current-quarter billings, RPO and guidance substantiate it.

Key Decisions for Investors

• Watch, rather than initiate, CHKP until the next earnings release confirms accelerating product/subscription bookings and RPO growth without gross-margin deterioration. Enter only if the stock has not already rerated materially and management raises full-year billings or revenue guidance; target a 10-15% relative rerating versus IGV over 3-6 months, with exit on a billings miss or reduced growth outlook.
• Use a relative-value expression: long CHKP / short FTNT in equal dollar beta-adjusted size for 3-6 months if CHKP shows recurring-revenue acceleration. The thesis isolates CHKP's margin and installed-base monetization against FTNT's greater exposure to hardware-cycle normalization; close if FTNT's secure-networking billings reaccelerate materially or CHKP's subscription mix stalls.
• Do not chase an AI multiple expansion against PANW or CRWD without evidence of share gains. If CHKP trades up on narrative alone while forward revenue estimates remain unchanged, consider selling upside calls or avoiding incremental exposure; multiple expansion unsupported by estimate revisions is vulnerable at the following earnings event.
• Set an earnings-monitoring alert for product revenue growth, deferred revenue/RPO, SASE adoption and operating-expense guidance. A combination of flat product growth and higher sales-and-marketing spend would invalidate the operating-leverage thesis and favors reducing exposure within days of results.